JOHNNY-VEGAS
3 weeks ago
Thanks James Keener.
$BDPT BioAdaptives, Inc.’s Board of Directors Approves a One-for-One Stock Dividend
GlobeNewswire6 hours ago
LAS VEGAS, Dec. 03, 2024 (GLOBE NEWSWIRE) -- via IBN – BioAdaptives Inc. (BDPTD.NaE) Board of Directors has approved a dividend to all common stockholders. They will receive matching shares for all of the shares they own on the Record Date.
CEO James Keener stated, “This dividend is designed to acknowledge your steadfast belief in our vision and to reward you for standing by us as valued stakeholders.”
Key Details:
Dividend Structure: One additional share of common stock for each share owned as of the record date.
Record Date: Projected for the second week of January 2025
Payment Date: Within 15 days from the Record Date
Keener added, “This special dividend aligns with our dedication to enhancing shareholder value while reinforcing our focus on long-term growth and success. The additional shares you will receive signify our shared optimism for the future and our determination to deliver
MC10459
3 weeks ago
The share price doesn't automatically drop when OS is increased. Dilution typically occurs when a company get a "toxic loan" with no intent of paying it back with cash. Instead, they're given the option to pay it back with discounted shares, which they do.
For example: the share price is at .05. The lender is given shares at .005 per share. Let's say the loan $100k. 20 million shares are paid to the lender and added to the outstanding share count. The lender has no intention of hanging onto the shares. They never do. So, they begin to dump. And they will dump at .05, .04, .03, 02. . . and less, thus making a killing. This drives down the share price. That's the effect of dilution.
Adding 4 million shares could drive down the price, if people choose to take profits---if they were green before or if this dividend makes them green. Myself, I'll hang onto to them and stay along for the ride. It could be very interesting.
Right now, this news has driven the pps up.
LJ-Bodhi
3 weeks ago
Let's unpack this dividend news. Every common shareholder will receive one additional share of stock for every share they own. Wow, great.....yes??? Well, let's just say the same thing in a different way. The company will automatically double the Outstanding Shares on a single day from 4 million to 8 million shares. Ummmm, that doesn't sound so good....no???
All things being equal, the market cap would remain the same, the OS will double, and the share price should plummet to half the price before the stock dividend to maintain equilibrium. As a singular event, the most likely thing this stock dividend will do is drop the price 50%. Sure, an investor will have double the shares, so gains from there will be nice. The question is how low the price will go once the downward pressure subsides from the dumping that will occur on the way down. Smart money will take the free shares and sell them as the price drops to get that free money. Then buy back up on the correction. This stock is going to be interesting. Now, if they could only sell products.....
Remember, no one will know how many shares the lender will convert until the April annual report, so there may be a very rude dilution awakening come next spring. Interesting stock indeed!
Giovanni
3 weeks ago
Thank you
BioAdaptives, Inc. Announces Institutional Review Board Approval of a Human Clinical Trial for Zeranovia™
LAS VEGAS, Nov. 25, 2024 (GLOBE NEWSWIRE) -- via IBN –BioAdaptives Inc. (OTC: BDPT) received approval today for a human clinical trial of its weight management product, Zeranovia™.
The trial, approved by an Institutional Review Board, will be managed and supervised by doctors in Las Vegas, Nevada. Sign-ups to participate in the clinical trial have been available on Zeranovia’s website. An excellent response from interested participants quickly filled available positions for the first trial stage. The first phase is designed to confirm dosing and determine if any new side effects are revealed. The next stage of the trial will be open to additional participants.
BioAdaptives™ CEO James Keener stated: “According to data from the National Institutes of Health's Office of Dietary Supplements (ODS), less than 1.0% of nutraceuticals sold in the United States undergo examination in human clinical trials.”
Keener continued: “We are committed to supplying the highest quality products with provable scientific results. Zeranovia’s™ success is based on a high-protein blend of vitamins, minerals, and five concentrated herbal supplements, four of which are adaptogens.”
Before moving Zeranovia™ to BioAdaptives™, Keener’s team spent almost one year in product development, including extensive lab work. Based on those efforts and the knowledge obtained, human clinical trials are expected to mirror the results already achieved. If so, this will be the first natural product that compares favorably to the synthetic medical treatments of GLP-1 and GIP.
LJ-Bodhi
1 month ago
Quarterly Report is out with zero revenues last quarter. The company is changing up its products so it will be a complete guess how future sales will progress. One thing is for certain, it is a rinse and repeat stinky pinky stock when it comes to issuing new shares to fund operations. They reported the following new shares which nearly maxes out the AS (currently 1.25 billion shares):
Common Stock
The Company is authorized to issue 1,250,000,000 shares of $0.0001 par value common stock.
As of September 30, 2024 and December 31, 2023, there were 1,231,728,974 and 895,760,225 shares of the Company’s common stock issued and outstanding, respectively. In addition, as of September 30, 2024 and December 31, 2023, there were 10,000 shares of the Company’s common stock issuable.
Fiscal year 2024
During the nine months ended September 30, 2024, the Company issued 335,968,749 shares of common stock valued at $202,643 for conversion of debt.
The company clearly disclosed it will issue more shares throughout the year for operating cash, so expect an 8K filing down the road increasing the AS above 1.25 billion shares to make room for the rinse and repeat. All the new shares will continue to put downward pressure on the stock price. It will be interesting if they can generate any future volume on product press releases or social media rumors. Seems dead for now.